Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ cr

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growing chronic portfolio. The company maintained its second position in India's chronic market and saw significant progress in its U.S. respiratory and biosimilar segments, with four major respiratory assets slated for launch by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJO7TED
via IFTTT